APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Attenuated Live Vaccine

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Selected research

Market Outlook & Growth Opportunities

Global Varicella Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchVaricella Attenuated Live Vaccine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Attenuated Live Vaccine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Varicella Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Attenuated Live Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

Read the full market overview

This report provides an overview of the global Varicella Attenuated Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Attenuated Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Attenuated Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Attenuated Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Attenuated Live Vaccine Segment by Company

Merck

BCHT

Shanghai Institute

GSK

Keygen

Green Cross

Biken

Shanghai Rongsheng Biotech

Changchun Changsheng Life Sciences Limited

Varicella Attenuated Live Vaccine Segment by Type

Monovalent Vaccine

Combination Vaccine

Varicella Attenuated Live Vaccine Segment by Application

Kids Injection

Adults Injection

Varicella Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Varicella Attenuated Live Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Varicella Attenuated Live Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Varicella Attenuated Live Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Varicella Attenuated Live Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Attenuated Live Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Varicella Attenuated Live Vaccine industry.

Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Varicella Attenuated Live Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Varicella Attenuated Live Vaccine Industry Trends Table 2. Varicella Attenuated Live Vaccine Industry Drivers Table 3. Varicella Attenuated Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Attenuated Live Vaccine Industry Restraints Table 5. Global Varicella Attenuated Live Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2021-2026) Table 7. Global Varicella Attenuated Live Vaccine Sales Volume by Company (k doses) & (2021-2026) Table 8. Global Varicella Attenuated Live Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Varicella Attenuated Live Vaccine Average Price (USD/dose) of Company (2021-2026) Table 10. Global Varicella Attenuated Live Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Varicella Attenuated Live Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Varicella Attenuated Live Vaccine Company, Product Type & Application Table 13. Global Varicella Attenuated Live Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monovalent Vaccine Table 18. Significant Companies of Combination Vaccine Table 19. Global Varicella Attenuated Live Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k doses) Table 20. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2021-2026) & (k doses) Table 21. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2027-2032) & (k doses) Table 22. Global Varicella Attenuated Live Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Varicella Attenuated Live Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Varicella Attenuated Live Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Varicella Attenuated Live Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Varicella Attenuated Live Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Varicella Attenuated Live Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Varicella Attenuated Live Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Kids Injection Table 30. Significant Companies of Adults Injection Table 31. Global Varicella Attenuated Live Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k doses) Table 32. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2021-2026) & (k doses) Table 33. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2027-2032) & (k doses) Table 34. Global Varicella Attenuated Live Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Varicella Attenuated Live Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Varicella Attenuated Live Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Varicella Attenuated Live Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Varicella Attenuated Live Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Varicella Attenuated Live Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Varicella Attenuated Live Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Varicella Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k doses) Table 42. Global Varicella Attenuated Live Vaccine Sales by Region (2021-2026) & (k doses) Table 43. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Varicella Attenuated Live Vaccine Sales by Region (2027-2032) & (k doses) Table 45. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Varicella Attenuated Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Varicella Attenuated Live Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Varicella Attenuated Live Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Varicella Attenuated Live Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Varicella Attenuated Live Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Varicella Attenuated Live Vaccine Market Average Price (USD/dose) by Region (2021-2026) Table 52. Global Varicella Attenuated Live Vaccine Market Average Price (USD/dose) by Region (2027-2032) Table 53. Global Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k doses) Table 54. Global Varicella Attenuated Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 56. Global Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Varicella Attenuated Live Vaccine Sales by Country (2027-2032) & (k doses) Table 58. Global Varicella Attenuated Live Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Varicella Attenuated Live Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Varicella Attenuated Live Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 66. Merck Varicella Attenuated Live Vaccine Product Portfolio Table 67. Merck Recent Development Table 68. BCHT Company Information Table 69. BCHT Business Overview Table 70. BCHT Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 71. BCHT Varicella Attenuated Live Vaccine Product Portfolio Table 72. BCHT Recent Development Table 73. Shanghai Institute Company Information Table 74. Shanghai Institute Business Overview Table 75. Shanghai Institute Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 76. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio Table 77. Shanghai Institute Recent Development Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 81. GSK Varicella Attenuated Live Vaccine Product Portfolio Table 82. GSK Recent Development Table 83. Keygen Company Information Table 84. Keygen Business Overview Table 85. Keygen Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 86. Keygen Varicella Attenuated Live Vaccine Product Portfolio Table 87. Keygen Recent Development Table 88. Green Cross Company Information Table 89. Green Cross Business Overview Table 90. Green Cross Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 91. Green Cross Varicella Attenuated Live Vaccine Product Portfolio Table 92. Green Cross Recent Development Table 93. Biken Company Information Table 94. Biken Business Overview Table 95. Biken Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 96. Biken Varicella Attenuated Live Vaccine Product Portfolio Table 97. Biken Recent Development Table 98. Shanghai Rongsheng Biotech Company Information Table 99. Shanghai Rongsheng Biotech Business Overview Table 100. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 101. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio Table 102. Shanghai Rongsheng Biotech Recent Development Table 103. Changchun Changsheng Life Sciences Limited Company Information Table 104. Changchun Changsheng Life Sciences Limited Business Overview Table 105. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 106. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio Table 107. Changchun Changsheng Life Sciences Limited Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Varicella Attenuated Live Vaccine Distributors List Table 111. Varicella Attenuated Live Vaccine Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Varicella Attenuated Live Vaccine Product Image Figure 2. Global Varicella Attenuated Live Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Varicella Attenuated Live Vaccine Sales (2021-2032) & (k doses) Figure 5. Global Varicella Attenuated Live Vaccine Sales Average Price (USD/dose) & (2021-2032) Figure 6. Global Varicella Attenuated Live Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monovalent Vaccine Image Figure 10. Combination Vaccine Image Figure 11. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k doses) Figure 12. Global Varicella Attenuated Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Varicella Attenuated Live Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Varicella Attenuated Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Varicella Attenuated Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Varicella Attenuated Live Vaccine Sales Value Share by Type (2021-2032) Figure 17. Kids Injection Image Figure 18. Adults Injection Image Figure 19. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k doses) Figure 20. Global Varicella Attenuated Live Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Varicella Attenuated Live Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Varicella Attenuated Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Varicella Attenuated Live Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Varicella Attenuated Live Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Varicella Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k doses) Figure 26. Global Varicella Attenuated Live Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Varicella Attenuated Live Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Varicella Attenuated Live Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Varicella Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Varicella Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Varicella Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Varicella Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Varicella Attenuated Live Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Varicella Attenuated Live Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccine
  • Combination Vaccine
Applications
  • Kids Injection
  • Adults Injection
Companies covered
  • Merck
  • BCHT
  • Shanghai Institute
  • GSK
  • Keygen
  • Green Cross
  • Biken
  • Shanghai Rongsheng Biotech
  • Changchun Changsheng Life Sciences Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Varicella Attenuated Live Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Varicella Attenuated Live Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Varicella Attenuated Live Vaccine Market Dynamics
  1. 2.1 Varicella Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Attenuated Live Vaccine Industry Restraints
3 Varicella Attenuated Live Vaccine Market by Company
  1. 3.1 Global Varicella Attenuated Live Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Varicella Attenuated Live Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Varicella Attenuated Live Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Varicella Attenuated Live Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Varicella Attenuated Live Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Varicella Attenuated Live Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Varicella Attenuated Live Vaccine Company Product Type and Application
  8. 3.8 Global Varicella Attenuated Live Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Varicella Attenuated Live Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Varicella Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Varicella Attenuated Live Vaccine Market by Type
  1. 4.1 Varicella Attenuated Live Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccine
  3. 4.1.2 Combination Vaccine
  4. 4.2 Global Varicella Attenuated Live Vaccine Sales Volume by Type
  5. 4.2.1 Global Varicella Attenuated Live Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Attenuated Live Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Varicella Attenuated Live Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Varicella Attenuated Live Vaccine Sales Value by Type
  9. 4.3.1 Global Varicella Attenuated Live Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Attenuated Live Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Varicella Attenuated Live Vaccine Sales Value Share by Type (2021-2032)
5 Varicella Attenuated Live Vaccine Market by Application
  1. 5.1 Varicella Attenuated Live Vaccine Application Introduction
  2. 5.1.1 Kids Injection
  3. 5.1.2 Adults Injection
  4. 5.2 Global Varicella Attenuated Live Vaccine Sales Volume by Application
  5. 5.2.1 Global Varicella Attenuated Live Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Varicella Attenuated Live Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Varicella Attenuated Live Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Varicella Attenuated Live Vaccine Sales Value by Application
  9. 5.3.1 Global Varicella Attenuated Live Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Varicella Attenuated Live Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Varicella Attenuated Live Vaccine Sales Value Share by Application (2021-2032)
6 Varicella Attenuated Live Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Attenuated Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Varicella Attenuated Live Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Varicella Attenuated Live Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Varicella Attenuated Live Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Varicella Attenuated Live Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Varicella Attenuated Live Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Varicella Attenuated Live Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Varicella Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Varicella Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Varicella Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Varicella Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value Share by Country, 2025 VS 2032
7 Varicella Attenuated Live Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Varicella Attenuated Live Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Varicella Attenuated Live Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Varicella Attenuated Live Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Varicella Attenuated Live Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Varicella Attenuated Live Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Varicella Attenuated Live Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Varicella Attenuated Live Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Varicella Attenuated Live Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Varicella Attenuated Live Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Varicella Attenuated Live Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 BCHT
  8. 8.2.1 BCHT Company Information
  9. 8.2.2 BCHT Business Overview
  10. 8.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
  12. 8.2.5 BCHT Recent Developments
  13. 8.3 Shanghai Institute
  14. 8.3.1 Shanghai Institute Company Information
  15. 8.3.2 Shanghai Institute Business Overview
  16. 8.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
  18. 8.3.5 Shanghai Institute Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Keygen
  26. 8.5.1 Keygen Company Information
  27. 8.5.2 Keygen Business Overview
  28. 8.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
  30. 8.5.5 Keygen Recent Developments
  31. 8.6 Green Cross
  32. 8.6.1 Green Cross Company Information
  33. 8.6.2 Green Cross Business Overview
  34. 8.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
  36. 8.6.5 Green Cross Recent Developments
  37. 8.7 Biken
  38. 8.7.1 Biken Company Information
  39. 8.7.2 Biken Business Overview
  40. 8.7.3 Biken Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
  42. 8.7.5 Biken Recent Developments
  43. 8.8 Shanghai Rongsheng Biotech
  44. 8.8.1 Shanghai Rongsheng Biotech Company Information
  45. 8.8.2 Shanghai Rongsheng Biotech Business Overview
  46. 8.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
  48. 8.8.5 Shanghai Rongsheng Biotech Recent Developments
  49. 8.9 Changchun Changsheng Life Sciences Limited
  50. 8.9.1 Changchun Changsheng Life Sciences Limited Company Information
  51. 8.9.2 Changchun Changsheng Life Sciences Limited Business Overview
  52. 8.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
  54. 8.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Attenuated Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Attenuated Live Vaccine Sales Mode & Process
  6. 9.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Attenuated Live Vaccine Distributors
  9. 9.2.3 Varicella Attenuated Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst